Mwana Africa unveils lab test results for Zimbabwe gold mine
AIM-listed mining company Mwana Africa has unveiled findings from a laboratory test conducted at its Freda Rebecca Gold Mine in Zimbabwe, revealing the presence of gold.
AIM-listed mining company Mwana Africa has unveiled findings from a laboratory test conducted at its Freda Rebecca Gold Mine in Zimbabwe, revealing the presence of gold.
The company, which commenced testwork in the mine during May 2012, reported that gold grades on the samples received ranged between 0.40 and 0.83 grammes per tonne.
Conventional cyanidation based on carbon-in-leach (CIL) process gave the highest metallurgical recoveries and a 64.3% gold recovery rate was recorded.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The company stated that construction of a pilot plan to validate the laboratory test results had commenced.
Kalaa Mpinga, Chief Executive Officer of Mwana, said: "The initial results from the test work on the tailings at Freda Rebecca are encouraging. Should the results from the pilot plant prove that retreatment of the tailings is viable, a full scale tailings retreatment plant has the potential to contribute significantly to annual gold production at Freda Rebecca."
Mwana Africa is a pan-African, multi-commodity resources company. Its principal operations and exploration activities cover gold, nickel and other base metals.
The company's share price was up 5.79% to 6.30p at 14:09 on Monday.
MF
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
GSK share price surges after $2.2bn Zantac drug settlement
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer
By Chris Newlands Published
-
Will the Autumn Budget impact investment markets?
Keir Starmer has warned the Autumn Budget will be “painful”. Will it impact investment markets and should you tweak your portfolio before 30 October?
By Katie Williams Published